Glycoengineered type II anti-CD20 monoclonal antibody that induces direct cell death and antibody-dependent/complement-dependent cytotoxicity of CD20+ B cells.
Glycoengineered humanized IgG1 type II anti-CD20 monoclonal antibody that binds CD20 on B cells; Fc afucosylation increases affinity for Fc-gamma RIII, enhancing antibody-dependent cellular cytotoxicity and phagocytosis; also triggers direct caspase-independent cell death and complement-dependent cytotoxicity, depleting CD20+ malignant B cells.
YES
DIRECT
Obinutuzumab binds CD20 on B cells and kills them via direct type II, caspase‑independent cell death, and by recruiting immune effectors—enhanced FcγRIIIa-mediated ADCC/ADCP and complement-dependent cytotoxicity (CDC).
Glycoengineered type II anti-CD20 monoclonal antibody that induces direct cell death and antibody-dependent/complement-dependent cytotoxicity of CD20+ B cells.
Glycoengineered humanized IgG1 type II anti-CD20 monoclonal antibody that binds CD20 on B cells; Fc afucosylation increases affinity for Fc-gamma RIII, enhancing antibody-dependent cellular cytotoxicity and phagocytosis; also triggers direct caspase-independent cell death and complement-dependent cytotoxicity, depleting CD20+ malignant B cells.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages CD16a on NK cells/macrophages to drive ADCC/ADCP (plus CDC and direct cell death) against CD20+ B cells. CD16a-expressing effector cells are not targeted or killed by the drug.
Glycoengineered type II anti-CD20 monoclonal antibody that induces direct cell death and antibody-dependent/complement-dependent cytotoxicity of CD20+ B cells.
Glycoengineered humanized IgG1 type II anti-CD20 monoclonal antibody that binds CD20 on B cells; Fc afucosylation increases affinity for Fc-gamma RIII, enhancing antibody-dependent cellular cytotoxicity and phagocytosis; also triggers direct caspase-independent cell death and complement-dependent cytotoxicity, depleting CD20+ malignant B cells.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages Fcγ receptors (including CD16b) on effector cells to trigger ADCC/ADCP and complement-mediated killing of CD20+ B cells. CD16b+ cells are effectors, not killed by the drug.
Humanized, Fc-engineered anti-CD19 IgG1 monoclonal antibody (Minjuvi) that binds CD19 on B cells, enhances ADCC/ADCP, and induces apoptosis.
Fc‑engineered humanized anti‑CD19 IgG1 monoclonal antibody that binds CD19 on B cells and enhances Fcγ receptor engagement, driving antibody‑dependent cellular cytotoxicity (ADCC) and antibody‑dependent cell‑mediated phagocytosis (ADCP), leading to depletion of CD19+ B cells and induction of apoptosis.
YES
DIRECT
Binds CD19 and engages Fcγ receptors on NK cells/macrophages to induce ADCC and ADCP, with additional direct apoptosis of CD19+ B cells.
Humanized, Fc-engineered anti-CD19 IgG1 monoclonal antibody (Minjuvi) that binds CD19 on B cells, enhances ADCC/ADCP, and induces apoptosis.
Fc‑engineered humanized anti‑CD19 IgG1 monoclonal antibody that binds CD19 on B cells and enhances Fcγ receptor engagement, driving antibody‑dependent cellular cytotoxicity (ADCC) and antibody‑dependent cell‑mediated phagocytosis (ADCP), leading to depletion of CD19+ B cells and induction of apoptosis.
NO
INDIRECT
Tafasitamab binds CD19 on B cells and engages FcγRs on NK cells/macrophages to trigger ADCC/ADCP, killing CD19+ B cells; FcγR-expressing effector cells are not killed.